This investigation or therapeutic intervention is of restricted gain for sufferers and may be carried out. In case of pT2 pN0 a taxane based polychemotherapy in addition trastuzumab monotherapy is suggested which could be followed in case of a HR+ tumor by neratinib monotherapy for up to 1 ca